Polycystic Kidney Disease – Current Treatment – Special Topics – Polycystic Kidney Disease – US
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the early stages, the disease is often asymptomatic and detectable only through diagnostic imaging of the kidney to reveal cysts. Until recently, treatment has focused on reducing blood pressure and pain and managing infection. However, the U.S. launch of Otsuka’s Jynarque (tolvaptan) in 2018 introduced the first disease-specific therapy for ADPKD. This therapy is approved for the treatment of ADPKD patients at risk of rapidly progressing. We examine how Jynarque’s launch has impacted ADPKD patient treatment and the challenges / opportunities that emerging therapies will face entering this market.
QUESTIONS ANSWERED
- How are patients diagnosed, categorized, and monitored? Is patient risk categorized? How frequently are patients monitored?
- Which patients are prescribed Jynarque? For which attributes do physicians think Jynarque performs best / worst? How has Jynarque’s launch affected the ADPKD treatment algorithm?
- Which clinical endpoints and trial comparators resonate most with physicians?
- Based on four hypothetical drug product profiles, which attributes are most important to physicians’ prescribing decisions?
CONTENT HIGHLIGHTS
- Geography: United States
- Primary research survey of 100 U.S. nephrologists
- Key drugs / drug classes covered: Jynarque, ACE / ARBs, CCBs, aldosterone agonists
- Key insights provided:
- Analysis of drug development opportunities
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician-reported recent / anticipated changes in brand usage or treatment approach
- Physician perceptions of unmet needs in the indication and related indications
PRODUCT DESCRIPTION
Special Topics provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand. It supports clinical development decisions by identifying key attributes and assessing areas of unmet need. Insights into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities are provided.
David Rees, M.Biochem., Ph.D., is a senior analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports on osteoporosis, autosomal dominant polycystic kidney disease, pulmonary hypertension, and type 2 diabetes. Previously, he was a postdoctoral research associate at Imperial College London and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize-winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate degree at the University of Bath.
Graeme Green, M.Sc., Ph.D., is the head of the Cardiovascular, Metabolic, Renal, and Hematology (CMRH) group at Clarivate, where he leads a team of analysts investigating indications ranging from type 2 diabetes to chronic heart failure. With more than 14 years of market experience in this space, he has managed and authored a vast array of content. Using various forecasting and assessment methodologies, he has written indication-specific insight reports and provided analysis on market dynamics, drug development, and corporate strategy. Prior to moving to the pharmaceutical sector, he worked for a financial management consultancy. Dr. Green holds a Ph.D. in molecular medical microbiology and an M.Sc. in forensic science from King’s College London.